Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Oral drug will rival Biogen, Novartis therapies

 
• By Mandy Jackson
  
FDA Approved text, inscription, phrase is written in a notebook that lies on a wooden table and a pen. Business concept.
Evrysdi is the first oral, but third disease-modifying therapy for SMA • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip